Research archive · This publication is preserved from the LEMMO Cancer Care library. Findings are specific to the study design and population and may not reflect current clinical practice.
Effect of concurrent chemotherapy and hyperthermia on outcome of preoperative radiotherapy of high-risk soft tissue sarcomas.
Strahlenther Onkol. 2013 Jun;189(6):482-5. doi: 10.1007/s00066-013-0312-7. Epub 2013 Apr 21.
Eckert F, Gani C, Kluba T, Mayer F, Kopp HG, Zips D, Bamberg M, Müller AC.
Source
Department of Radiation Oncology, Eberhard-Karls-University Tübingen, Hoppe-Seyler-Strasse 3, Tübingen, Germany.
Abstract
BACKGROUND AND PURPOSE:
As treatment results for high-risk soft tissue sarcoma are still disappointing, treatment intensification is warranted. We performed a retrospective analysis of multimodal preoperative treatment to evaluate the additional effect of concurrent chemotherapy and/or locoregionalhyperthermia in comparison to radiotherapy alone.
PATIENTS AND METHODS:
Between 1999 and 2011, 28 patients were treated with neoadjuvant radiotherapy to a median 45 Gy for high-risk soft tissue sarcoma. All tumors were deep-seated and grade 2 or 3, 86% (n = 24) larger than 5 cm. Multimodal treatment (n = 12) consisted of ifosfamide (n = 7), locoregional hyperthermia (n = 3), or both modalities (n = 2) concurrent to radiotherapy.
RESULTS:
Prognostic factors (grade, size, histology, location) were balanced in the groups with and without concurrent multimodal treatment. There was a significant improvement of disease-specific survival (100% vs. 70% at 3 years, p = 0.03) with multimodal treatment. Distant metastases-free survival was influenced, but was not statistically significant. Local control and disease-free survival did not differ in the two groups.
CONCLUSION:
Our data suggest that multimodal treatment with ifosfamide and/or locoregional hyperthermia in combination with neoadjuvant radiotherapy might improve outcome in high-risk soft tissue sarcomas